Hiromi Muramatsu - Concepedia

Author

Hiromi Muramatsu

University of Pennsylvania ORCID

Also Known As

H Muramatsu, H. MURAMATSU, H. Muramatsu, Hiromi MURAMATSU, Hiromi Muramatsu, Muramatsu, Hiromi, Sung, Molly M. H.

130

Publications

11.9K

Citations

H-Index

113

Concepts

All Affiliations

University of Pennsylvania Acuitas Therapeutics (Canada)Nippon Medical School BioNTech (Germany)Icahn School of Medicine at Mount Sinai

About

Hiromi Muramatsu is an author at University of Pennsylvania specializing in medicine, immunology, and vaccine development.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	32	6.4K
2	Natural Sciences	5	5	1.7K
3	Health Sciences	4	4	75
4	Engineering	2	2	250
5	Public Health	1	1	35

Hiromi Muramatsu

Publications

11.4K

Citations

H-Index

Page 1

	Year	Citations
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability Katalin Karikó, Hiromi Muramatsu, Frank A. Welsh, Molecular Therapy	2008	1.8K
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes Norbert Pardi, Steven Tuyishime, Hiromi Muramatsu, Journal of Controlled Release NanotherapeuticsBiochemistryNatural SciencesLipid NanoparticlesMolecular Biology	2015	980
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination Norbert Pardi, Michael J. Hogan, Rebecca S. Pelc, Nature VaccinationVaccinologyVaccine DevelopmentVaccine TargetZika Virus Protection	2017	872
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA Katalin Karikó, Hiromi Muramatsu, János Ludwig, Nucleic Acids Research Immune ActivationInnate Immune SystemImmunologyInnate ImmunityImmunotherapy	2011	854
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses Mohamad‐Gabriel Alameh, István Tombácz, Emily Bettini, Immunity VaccinationNanomedicineCross-protectionMucosal VaccinationVaccine Development	2021	659
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation Bart R. Anderson, Hiromi Muramatsu, Subba Rao Nallagatla, Nucleic Acids Research Molecular RegulationMolecular BiologyPseudouridine-containing MrnasProtein SynthesisTranscriptional Regulation	2010	643
A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA Markus Baiersdörfer, Gábor Boros, Hiromi Muramatsu, Molecular Therapy — Nucleic Acids	2019	507
Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses Norbert Pardi, Michael J. Hogan, Martin S. Naradikian, The Journal of Experimental Medicine	2018	501
SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation Katlyn Lederer, Diana Castaño, Daniela Gómez, Immunity VaccinationVaccine DevelopmentVaccine TargetImmunologyNeutralizing Antibody Generation	2020	386
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice Dorottya Laczkó, Michael J. Hogan, Sushila A. Toulmin, Immunity VaccinationHumoral Immune ResponsesVaccine DevelopmentVaccine TargetImmunology	2020	376

Page 1